Information Provided By:
Fly News Breaks for June 28, 2016
NVAX
Jun 28, 2016 | 06:19 EDT
Piper Jaffray analyst Edward Tenthoff recommends owning shares of Novavax into the company's Phase III RSV vaccine data in Q3. Based on the Phase II study, we are confident the trial is sufficiently powered to achieve statistical significance, Tenthoff tells investors in a research note. Novavax could be an acquisition target by a larger vaccine player, the analyst contends. He reiterates the company as a top pick with an Overweight rating and $14 price target.
News For NVAX From the Last 2 Days
There are no results for your query NVAX